Development of New Molecularly Targeted Agents in Inflammatory Bowel Disease

Abstract

Inflammatory bowel disease (IBD) is a multifactorial disorder resulting from a complex interplay among genetic predisposition, immune dysregulation, intestinal microbiota, and environmental factors. This dynamic interaction leads to aberrant immune activation within the gastrointestinal tract, ultimately leading to chronic inflammation. Recent advances in elucidating the pathophysiology of this disease have facilitated the development of molecularly targeted therapies. This review provides a critical appraisal of these emerging therapeutic strategies and emphasizes their potential impact on disease management.